Source-grounded facts extracted from Yubo International Biotech Ltd's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Yubo International Biotech Ltd engaged HCL, PLLC as its auditor.
“On January 13, 2026, the Company engaged HCL, PLLC (“HCL”) as its new independent registered public accountant to audit the Company’s consolidated financial statements for the year ended December 31, 2025, with immediate effect.”
HHL LLP resigned as auditor of Yubo International Biotech Ltd.
“On January 13, 2026, HHL LLP (“HHL”) tendered its resignation as the independent registered public accounting firm to Yubo International Biotech Limited”
Yubo International Biotech Ltd engaged HHL LLP as its auditor.
“On December 30, 2024, the Company engaged HHL LLP (“HHL”) as its new independent registered public accountant, effective January 2, 2025.”
Yubo International Biotech Ltd dismissed Michael T. Studer CPA P.C. as its auditor.
“On December 26, 2024, Yubo International Biotech Limited, a New York corporation (the “Company”), dismissed Michael T. Studer CPA P.C. (“MTS CPA”) as the Company’s independent registered public accounting firm”
Yubo International Biotech Ltd engaged HHL Advisors Group as its auditor.
“On December 26, 2024, the Company engaged HHL Advisors Group (“HHL”) as its new independent registered public accountant, effective January 2, 2025.”
Yubo International Biotech Ltd dismissed Michael T. Studer CPA P.C. as its auditor.
“On December 26, 2024, Yubo International Biotech Limited, a New York corporation (the “Company”), dismissed Michael T. Studer CPA P.C. (“MTS CPA”) as the Company’s independent registered public accounting firm”
Yubo International Biotech Ltd entered into Securities Purchase Agreement with World Precision Medicine Technology Limited valued at $819,229 (effective 2022-09-02).
“On September 2, 2022, Yubo International Biotech Limited, a New York Corporation (the “ Company ”) entered into a Securities Purchase Agreement with World Precision Medicine Technology Limited (the “ Purchaser ”), as further amended by an Amendment to Securities Purchase Agreement, effective as of September 2, 2022, by and between the Company and the Purchaser (as amended, the “ Securities Purchase Agreement ”), pursuant to which the Company agreed to sell and issue to the Purchaser an aggregate of 1,638,458 shares (the “ Shares ”) of Class A Common Stock, par value $0.001 per share, of the Company, at $0.50 per share, for gross proceeds of $819,229.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.